It has been shown in several malignancies, including lung cancer, renal cell carcinoma, and melanoma, that higher TMB is associated with responses to PD‐1/PD‐L1 inhibitors, but no such clinical trials have been conducted in NPC. The gene discussed is CD274; the disease is renal cell carcinoma.